Adoram Therapeutics
Phase 3Adoram is a Swiss-based biotech spin-off from the University of Geneva, leveraging the advantages of allosteric biochemistry to create new treatments for patients with solid tumors or immune-based diseases.
Founded
2021
Focus
Small Molecules
About
Adoram is a Swiss-based biotech spin-off from the University of Geneva, leveraging the advantages of allosteric biochemistry to create new treatments for patients with solid tumors or immune-based diseases.
Funding History
1Total raised: $4M
Seed$4MBioMedPartnersFeb 15, 2022
Company Info
TypePrivate
Founded2021
LocationBasel, Switzerland
StagePhase 3
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile